STXS

Stereotaxis, Inc. 10-Q Summary: Quarter Ended March 31, 2008

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2008. Stereotaxis, Inc. designs, manufactures, and markets the NIOBE magnetic navigation system and the ODYSSEY information management system for interventional cardiology procedures. The company operates primarily in the U.S., Europe, and Asia.

Key Financial Metrics

Liquidity: The company holds $10.97 million in cash and cash equivalents. It maintains a $30 million working capital line of credit with approximately $25 million unused, though borrowing capacity based on qualifying assets is approximately $11.1 million. The company also secured a $20 million unsecured loan commitment from shareholders in February 2008.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 23% year-over-year. System sales revenue dropped 39% (from $7.2M to $4.4M) due to a decrease in systems delivered (four vs. six). Conversely, revenue from disposables, service, and accessories increased 36% (from $2.0M to $2.7M) driven by a larger installed base.
• Expense Increases: Sales and marketing expenses rose 26% to $7.7 million due to expanded headcount and marketing programs. General and administrative expenses increased 11% to $5.5 million, largely due to European expansion costs. Research and development expenses decreased 17% to $4.7 million.
• Investment Impairment: The company recorded a $31,598 "other-than-temporary" impairment charge on $500,000 of auction rate securities (ARS) due to liquidity issues in the credit markets. These securities were reclassified from short-term to long-term investments.
• Interest Expense: Interest expense increased significantly to $403,000 from $80,000, primarily due to the amortization of warrant costs associated with the new shareholder loan facility.

Guidance, Outlook, and Risks

• Cash Flow Outlook: Management expects negative cash flow from operations to continue through 2008. The company anticipates funding operations through existing cash resources, the $20 million shareholder loan facility, and the bank line of credit.
• Capital Needs: While current resources are deemed sufficient for the next 12 months, the company may require additional financing. There is no assurance that future financing will be available on acceptable terms or at all.
• Market Risks:
  • Liquidity Risk: The company holds $469,000 in auction rate securities that may not be liquidatable until maturity (2034) or may require selling at a loss if market conditions do not improve.
  • Currency Risk: A 10% fluctuation in the Euro exchange rate could impact revenues by 2% to 3%.
• Backlog: Purchase orders and commitments for systems and integrated cath lab displays were approximately $66 million as of March 31, 2008. Management notes that these orders are subject to contingencies and may be revised or cancelled.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $10.97 million cash balance and the $20 million shareholder loan commitment to cover the projected negative operating cash flow for the remainder of 2008.
• Auction Rate Securities: Assess the risk associated with the $469,000 investment in illiquid auction rate securities and the potential for further impairment charges.
• Revenue Recognition: Review the backlog of $66 million and the specific contingencies attached to these orders to gauge future revenue certainty.
• Debt Covenants: Confirm continued compliance with the "tangible net worth" covenant (minimum $5 million) under the bank loan agreement.
• Expense Trajectory: Monitor the trend of increasing sales and marketing expenses against the declining system sales volume to evaluate path to profitability.